3天2板未名医药：公司存在触发其他风险警示的情形

Group 1 - The core point of the article is that Weiming Pharmaceutical's stock has experienced significant price fluctuations, with a cumulative increase of over 20% in closing prices over three consecutive trading days [1] - The company announced that its subsidiary, Tianjin Weiming, has been subjected to production and sales suspension measures since April 22, 2025, which has a significant impact on the company's operations [1] - If Tianjin Weiming is unable to resume production within three months, the company may trigger additional risk warnings [1]